Pacira BioSciences, Inc. (Nasdaq: PCRX), a prominent biopharmaceutical company recognized for its dedication to developing innovative non-opioid pain management therapies, has taken legal action to protect its proprietary technology. On November 26, 2025, the company announced it had filed a patent infringement lawsuit in the United States District Court for the District of Delaware against The WhiteOak Group, Inc. and Qilu Pharmaceutical (Hainan) Co., Ltd. The lawsuit pertains to alleged infringements related to EXPAREL, a bupivacaine liposome injectable suspension utilized for postoperative pain management.
The legal filing is significant not only for its implications for the companies involved but also for its potential impact on the market for EXPAREL. Under the provisions of the Hatch-Waxman Act, this lawsuit triggers a 30-month stay on the approval of any generic versions of EXPAREL. This provision is designed to encourage innovation in pharmaceutical research while allowing patent holders time to defend their intellectual property.
Pacira BioSciences has seen notable growth over the past year, reflecting the increasing demand for its innovative pain management solutions. The company’s revenue per employee has reached $576,662 during the trailing twelve months, representing a 6.49% increase in revenue for the third quarter of 2025, amounting to a total cumulative revenue of $717 million. This figure marks a new high for the company, underscoring its successful operational strategies and the effectiveness of its product line.
Despite this positive trajectory, Pacira’s ranking compared to industry peers has slipped, moving from 970 in Q2 2025 to 1122 in the current rankings. The company currently employs 1,243 individuals, and within the healthcare sector, 143 other companies have reported higher revenue per employee ratios, highlighting competitive performance metrics in the biopharmaceutical industry.
As Pacira BioSciences enters this litigation phase, the company aims to fortify its market position for EXPAREL while also reinforcing its commitment to patients requiring effective pain management solutions. The outcome of this lawsuit could set important precedents for the intellectual property landscape within the pharmaceutical industry, especially concerning non-opioid treatment modalities.
Comments